Successes, failures and new perspectives of idiotypic vaccination for B-cell non-Hodgkin lymphomas

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 5, 2013, Pages 1078-1083

  Muraro, Elena ^a   Martorelli, Debora ^a   Dolcetti, Riccardo ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Cancer; Epitope; Idiotype; Lymphoma; Vaccine

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LYMPHOMA VACCINE; PREDNISONE; RITUXIMAB; VINCRISTINE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER IMMUNIZATION; CANCER RESEARCH; DISEASE FREE SURVIVAL; DISEASE MARKER; DRUG FORMULATION; DRUG MEGADOSE; FOLLICULAR LYMPHOMA; HUMAN; LYMPHOMA; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; NOTE; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); STUDY DESIGN; TREATMENT FAILURE; TREATMENT RESPONSE;

CANCER; EPITOPE; IDIOTYPE; LYMPHOMA; VACCINE;

CANCER VACCINES; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOGLOBULIN IDIOTYPES; LYMPHOMA, B-CELL; VACCINATION;

EID: 84878790876     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.23970     Document Type: Note

References (46)

1. Cecco S, Muraro E, Giacomin E, Martorelli D, Lazzarini R, Baldo P, et al. Cancer vaccines in phase II/III clinical trials: state of the art and future perspectives. Curr Cancer Drug Targets 2011; 11:85-102; PMID:21062241; http://dx.doi.org/10.2174/156800911793743664.
2. Schuster SJ, Neelapu SS, Gause BL, Janik JE, Muggia FM, Gockerman JP, et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol 2011; 29:2787-94; PMID:21632504; http://dx.doi.org/10.1200/JCO.2010.33.3005.
3. Ansell SM, Suman VJ. Identifying patients with follicular lymphoma who are likely to benefit from an idiotype vaccine. J Clin Oncol 2011; 29:2748-9; PMID:21632499; http://dx.doi.org/10.1200/JCO.2011.35.8812.
4. Huff CA, Matsui W, Smith BD, Jones RJ. The paradox of response and survival in cancer therapeutics. Blood 2006; 107:431-4; PMID:16150939; http://dx.doi.org/10.1182/blood-2005-06-2517.
5. Schuster SJ, Neelapu SS, Santos CF, Popa-McKiver MA, McCord AM, Kwak LW. Idiotype vaccination as consolidation therapy: time for integration into standard of care for follicular lymphoma? J Clin Oncol 2011; 29:4845-6; PMID:22042953; http://dx.doi.org/10.1200/JCO.2011.38.6094.
6. Brody JD, Ai WZ, Czerwinski DK, Torchia JA, Levy M, Advani RH, et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol 2010; 28:4324-32; PMID:20697067; http://dx.doi.org/10.1200/JCO.2010.28.9793.
7. Hollander N. Immunotherapy for B-cell lymphoma: current status and prospective advances. Front Immunol 2012; 3:3; PMID:22566889; http://dx.doi.org/10.3389/fimmu.2012.00003.
8. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351:2159-69; PMID:15548776; http://dx.doi.org/10.1056/NEJMoa041869.
9. Bendandi M. Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures. Nat Rev Cancer 2009; 9:675-81; PMID:19701243; http://dx.doi.org/10.1038/nrc2717.
10. Miller RA, Maloney DG, Warnke R, Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 1982; 306:517-22; PMID:6173751; http://dx.doi.org/10.1056/NEJM198203043060906.
11. Bendandi M, Gocke CD, Kobrin CB, Benko FA, Sternas LA, Pennington R, et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 1999; 5:1171-7; PMID:10502821; http://dx.doi.org/10.1038/13928.
12. Timmerman JM, Vose JM, Czerwinski DK, Weng WK, Ingolia D, Mayo M, et al. Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma. Leuk Lymphoma 2009; 50:37-46; PMID:19125383; http://dx.doi.org/10.1080/10428190802563355.
13. Inogès S, Rodrìguez-Calvillo M, Zabalegui N, Lòpez-Dìaz de Cerio A, Villanueva H, Soria E, et al.; Grupo Español de Linfomas/Trasplante Autologo de Medula Oseo study group; Programa para el Estudio y Tratamiento de Hemopatias Malignas study group. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J Natl Cancer Inst 2006; 98:1292-301; PMID:16985248; http://dx.doi.org/10.1093/jnci/djj358.
14. Redfern CH, Guthrie TH, Bessudo A, Densmore JJ, Holman PR, Janakiraman N, et al. Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses. J Clin Oncol 2006; 24:3107-12; PMID:16754937; http://dx.doi.org/10.1200/JCO.2005. 04.4289.
15. Freedman A, Neelapu SS, Nichols C, Robertson MJ, Djulbegovic B, Winter JN, et al. Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. J Clin Oncol 2009; 27:3036-43; PMID:19414675; http://dx.doi.org/10.1200/JCO.2008.19.8903.
16. Schlom J. Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst 2012; 104:599-613; PMID:22395641; http://dx.doi.org/10.1093/ jnci/djs033.
17. Reitan SK, Hannestad K. A syngeneic idiotype is immunogenic when borne by IgM but tolerogenic when joined to IgG. Eur J Immunol 1995; 25:1601-8; PMID:7614988; http://dx.doi.org/10.1002/eji.1830250620.
18. Reitan SK, Hannestad K. Immunoglobulin heavy chain constant regions regulate immunity and tolerance to idiotypes of antibody variable regions. Proc Natl Acad Sci U S A 2002; 99:7588-93; PMID:12032327; http://dx.doi.org/10.1073/ pnas.052150899.
19. Park HJ, Neelapu SS. Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials. Br J Haematol 2008; 142:179-91; PMID:18422783; http://dx.doi.org/10.1111/j.1365-2141.2008.07143.x.
20. Gulley JL. Toward an off-the-shelf vaccine for B-cell malignancies. Blood 2012; 120:1539-40; PMID:22918421; http://dx.doi.org/10.1182/blood-2012-07- 435123.
21. Agathangelidis A, Darzentas N, Hadzidimitriou A, Brochet X, Murray F, Yan XJ, et al. Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. Blood 2012; 119:4467-75; PMID:22415752; http://dx.doi.org/10.1182/blood-2011-11- 393694.
22. Bomben R, Dal Bo M, Capello D, Forconi F, Maffei R, Laurenti L, et al. Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study. Br J Haematol 2009; 144:492-506; PMID:19036101; http://dx.doi.org/10.1111/j.1365- 2141.2008.07469.x.
23. De Re V, De Vita S, Gasparotto D, Marzotto A, Carbone A, Ferraccioli G, et al. Salivary gland B cell lymphoproliferative disorders in Sjögren's syndrome present a restricted use of antigen receptor gene segments similar to those used by hepatitis C virus-associated non-Hodgkins's lymphomas. Eur J Immunol 2002; 32:903-10; PMID:11870635; http://dx.doi.org/10.1002/1521- 4141(200203)32:3〈903::AIDIMMU903〉3.0.CO;2-D.
24. Martorelli D, Guidoboni M, De Re V, Muraro E, Turrini R, Merlo A, et al. IGKV3 proteins as candidate "off-the-shelf" vaccines for kappa-light chain-restricted B-cell non-Hodgkin lymphomas. Clin Cancer Res 2012; 18:4080-91; PMID:22705988; http://dx.doi.org/10.1158/1078-0432.CCR-12-0763.
25. Miklos JA, Swerdlow SH, Bahler DW. Salivary gland mucosa-associated lymphoid tissue lymphoma immunoglobulin V(H) genes show frequent use of V1-69 with distinctive CDR3 features. Blood 2000; 95:3878-84; PMID:10845923.
26. Sakuma H, Nakamura T, Uemura N, Chiba T, Sugiyama T, Asaka M, et al. Immunoglobulin VH gene analysis in gastric MALT lymphomas. Mod Pathol 2007; 20:460-6; PMID:17334352; http://dx.doi.org/10.1038/modpathol.3800758.
27. Tobin G, Thunberg U, Karlsson K, Murray F, Laurell A, Willander K, et al. Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia. Blood 2004; 104:2879-85; PMID:15217826; http://dx.doi.org/10.1182/blood-2004-01- 0132.
28. Widhopf GF 2 nd, Rassenti LZ, Toy TL, Gribben JG, Wierda WG, Kipps TJ. Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins. Blood 2004; 104:2499-504; PMID:15217828; http://dx.doi.org/10.1182/blood-2004-03-0818.
29. Trojan A, Schultze JL, Witzens M, Vonderheide RH, Ladetto M, Donovan JW, et al. Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies. Nat Med 2000; 6:667-72; PMID:10835683; http://dx.doi.org/10.1038/76243.
30. Xiaoling G, Ying L, Jing L, Huifang L, Xia Z, Qingqing F, et al. Induction of anti B-cell malignance CTL response by subfamily-shared peptides derived from variable domain of immunoglobulin heavy chain. Cancer Immunol Immunother 2005; 54:1106-14; PMID:15889252; http://dx.doi.org/10.1007/s00262- 005-0696-z.
31. Weng J, Cha SC, Matsueda S, Alatrash G, Popescu MS, Yi Q, et al. Targeting human B-cell malignancies through Ig light chain-specific cytotoxic T lymphocytes. Clin Cancer Res 2011; 17:5945-52; PMID:21813633; http://dx.doi.org/10.1158/1078-0432.CCR-11-0970.
32. Weng J, Rawal S, Chu F, Park HJ, Sharma R, Delgado DA, et al. TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas. Blood 2012; 120:1613-23; PMID:22645177; http://dx.doi.org/10.1182/blood-2011-09- 382838.
33. Bende RJ, Aarts WM, Riedl RG, de Jong D, Pals ST, van Noesel CJ. Among B cell non-Hodgkin's lymphomas, MALT lymphomas express a unique antibody repertoire with frequent rheumatoid factor reactivity. J Exp Med 2005; 201:1229-41; PMID:15837810; http://dx.doi.org/10.1084/jem.20050068.
34. Chan CH, Hadlock KG, Foung SK, Levy S. V(H)1-69 gene is preferentially used by hepatitis C virus-associated B cell lymphomas and by normal B cells responding to the E2 viral antigen. Blood 2001; 97:1023-6; PMID:11159532; http://dx.doi.org/10.1182/blood.V97.4.1023.
35. Craig VJ, Arnold I, Gerke C, Huynh MQ, Wündisch T, Neubauer A, et al. Gastric MALT lymphoma B cells express polyreactive, somatically mutated immunoglobulins. Blood 2010; 115:581-91; PMID:19965661; http://dx.doi.org/10. 1182/blood-2009-06-228015.
36. Ivanovski M, Silvestri F, Pozzato G, Anand S, Mazzaro C, Burrone OR, et al. Somatic hypermutation, clonal diversity, and preferential expression of the VH 51p1/VL kv325 immunoglobulin gene combination in hepatitis C virus-associated immunocytomas. Blood 1998; 91:2433-42; PMID:9516143.
37. Küppers R, Rajewsky K, Hansmann ML. Diffuse large cell lymphomas are derived from mature B cells carrying V region genes with a high load of somatic mutation and evidence of selection for antibody expression. Eur J Immunol 1997; 27:1398-405; PMID:9209491; http://dx.doi.org/10.1002/eji.1830270616.
38. Smilevska T, Tsakou E, Hadzidimitriou A, Bikos V, Stavroyianni N, Laoutaris N, et al. Immunoglobulin kappa gene repertoire and somatic hypermutation patterns in follicular lymphoma. Blood Cells Mol Dis 2008; 41:215-8; PMID:18640859; http://dx.doi.org/10.1016/j.bcmd.2008.06.002.
39. Butterfield LH, Palucka AK, Britten CM, Dhodapkar MV, Håkansson L, Janetzki S, et al. Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res 2011; 17:3064-76; PMID:21558394; http://dx.doi.org/10.1158/1078-0432.CCR-10-2234.
40. Disis ML. Immunologic biomarkers as correlates of clinical response to cancer immunotherapy. Cancer Immunol Immunother 2011; 60:433-42; PMID:21221967; http://dx.doi.org/10.1007/s00262-010-0960-8.
41. Gnjatic S, Wheeler C, Ebner M, Ritter E, Murray A, Altorki NK, et al. Seromic analysis of antibody responses in non-small cell lung cancer patients and healthy donors using conformational protein arrays. J Immunol Methods 2009; 341:50-8; PMID:19041653; http://dx.doi.org/10.1016/j.jim.2008.10.016.
42. Gnjatic S, Ritter E, Büchler MW, Giese NA, Brors B, Frei C, et al. Seromic profiling of ovarian and pancreatic cancer. Proc Natl Acad Sci U S A 2010; 107:5088-93; PMID:20194765; http://dx.doi.org/10.1073/pnas.0914213107.
43. Gulley JL, Arlen PM, Madan RA, Tsang KY, Pazdur MP, Skarupa L, et al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother 2010; 59:663-74; PMID:19890632; http://dx.doi.org/10. 1007/s00262-009-0782-8.
44. Kufe DW. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer 2009; 9:874-85; PMID:19935676; http://dx.doi.org/10.1038/nrc2761.
45. Baskar S, Kobrin CB, Kwak LW. Autologous lymphoma vaccines induce human T cell responses against multiple, unique epitopes. J Clin Invest 2004; 113:1498-510; PMID:15146248.
46. Holman PR, Costello C, deMagalhaes-Silverman M, Corringham S, Castro J, Ball ED. Idiotype immunization following high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2012; 18:257-64; PMID:21736867; http://dx.doi.org/10.1016/j.bbmt.2011.06.011.